Group items tagged

Britain's antitrust regulator, the Competition and Markets Authority (CMA) on Wednesday announced that it is investigating the acquisition of LloydsDirect by Pharmacy2U last year, and has launched its first phase of the merger inquiry. The completed deal between two of the UK's foremost online pharmacies was announced in a joint statement issued on 9 October, confirming that they would operate as Pharmacy2U. Commenting on the purchase, Kevin Heath, CEO of Pharmacy2U, then said: "Combining the best of both of our businesses, we can provide patients with greater access and convenience." The regulator is considering "whether it is or may be the case that this merger has resulted in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation has resulted, or may be expected to result, in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services."

The Royal Pharmaceutical Society (RPS) and the Pharmacists' Defence Association (PDA) have responded to the Department of Health and Social Care (DHSC) consultation on pharmacy supervision, which was launched in early December last year. The DSHC set out proposals to amend the Medicines Act 1968 and The Human Medicines Regulations 2012 to allow registered pharmacy technicians to work without direct supervision, which in turn will help free up pharmacists to provide more clinical care and reduce GP appointments. While the RPS supported the legislative change, it highlighted a range of topics that should be considered and clarified in regulations and guidance. According to RPS, the new concept of 'authorisation', including around documentation, accountability, and the role of superintendent pharmacist and responsible pharmacist, needs clarification.

PBR Staff Writer Published 01 May 2014 The US Food and Drug Administration (FDA) has approved GlaxoSmithKline's (GSK) Incruse Ellipta (umeclidinium) for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Umeclidinium is a once-daily long-acting muscarinic antagonist (LAMA), a type of bronchodilator also known as an anticholinergic.

What Is Appendicitis? How to diagnose Appendicitis? Where is Appendix pain located In this article, we hope you can find all of your answers related to Appendicitis. We covered everything about Appendicitis. We discussed types, causes, symptoms, tests, and treatment of Appendicitis.

Appendicitis is an inflammation of the appendix, which is a small tube of intestinal tissue that projects from the large intestine. While the appendix does not seem to have a particular function, one theory suggests that it acts as a storehouse of good bacteria and boosts immunity after diarrheal illness. However, some experts believe the appendix is just a purposeless remnant from our evolutionary past. One thing we're sure of is that we can live without it, without any apparent consequences.

Before we go into the details, the Merit-based Incentive Payment System (MIPS) comes under the direct obligation of the Medicare Access and CHIP Reauthorization Act (MACRA), the law that regulates the incentive program across the US.

Physicians were quite unsure about how to act to these facts. Of course, medical billing outsourcing companies can't proceed without their clients' consent. Therefore, HHS took it upon itself to explain all the complications that restrict healthcare professionals to benefit from this program.

The world at large holds its breath as life is about to normalize. It is going to take more than just the will to reopen amidst COVID-19, especially the schools. What we need to do is act upon a persistent, consistent, and watchful approach. Because one small mistake can cost us precious lives.

ITV on Tuesday (Aug 15) said it had agreed to invest in pain relief brand Flarin Holdings Ltd, making it the British broadcaster's first consumer healthcare investment. The company has agreed to subscribe for £2 million worth of shares in Flarin, with an option to subscribe for two more tranches of 1.5 million pounds each. In return, Flarin would get advertising space across ITV's channels and ITVX. ITV said its investment will "help Flarin build mass market brand awareness by bringing the brand to millions of consumers via ITV platforms. This will be a step change in the size of the campaign and the approach to scaling the Flarin brand to date." Director of ITV AdVentures, Sheena Amin, said: "It's fantastic to be announcing our latest Media for Equity investment into Flarin. With its innovative and patented lipid technology, Flarin offers many unique benefits to those suffering from joint and muscular pain compared to any other product on the market. Flarin is already one of the fastest growing analgesics in the market and I am confident that we will see the company grow to new heights following a brand building campaign across ITV."

The Pharmaceutical Services Negotiating Committee (PSNC) has refused to accept the Department of Health and Social Care (DHSC)'s decision to get rid of 'transitional payments' from February 2023. The pharmacy negotiator said that 'any reductions in payments at this point will be impossible for community pharmacy contractors to manage financially.' "We are also continuing to be clear with officials and ministers that CPCF funding needs an urgent uplift to help businesses to cope with soaring costs being driven by inflation and the workforce crisis. We put a comprehensive business case to the government for this uplift in the last CPCF negotiations." The latest 'transitional payments decision' by the Department follows the announcement last year that the value of the these payments would be phased down over the second half of 2022/23 and will be based on the latest monitoring and analysis of funding delivery. PSNC says it submitted a fully-costed bid for a 'Pharmacy First' service in its last round of negotiations alongside the case for an uplift to core CPCF funding. Both of these were refused.

Medical malpractice is a serious issue, and if you are ever a victim of it, you need to know what to do. More often than not, people do not even know that they are victims of medical malpractice until it is too late. This blog post will discuss six important things that you need to know about medical malpractice. Read on to learn more. IT CAN HAPPEN TO ANYONE First and foremost, medical malpractice can happen to anyone. It does not discriminate based on age, gender, or race. If you have been a victim of medical negligence, then you need to take action. However, many people do not even know that they are victims of medical malpractice until it is too late. This is because the symptoms of medical malpractice can often mimic other conditions or diseases. As such, it is important to be aware of the signs and symptoms of medical malpractice so that you can take action as soon as possible. Some of the most common signs and symptoms of medical malpractice include sudden and unexpected death, severe or permanent injuries, disfigurement, as well as loss of limb. If you or a loved one have experienced any of these symptoms, then it is important to seek legal help as soon as possible. An experienced medical malpractice lawyer will be able to help you investigate your case and determine if you have a valid claim. In this case, take the time to explore online sources where you may come across the websites of some of the most reputable lawyers. This is where you will have the chance to learn about medical malpractice and what you can do to take action. Rest assured that with the help of a competent lawyer, you will be able to get the justice and compensation that you deserve.

The Department of Health and Social Care (DHSC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) have added five more medicines that cannot be hoarded or exported from the UK market. The government has taken the following action to address the "critical shortage" of attention deficit hyperactivity disorder (ADHD) drugs. In a crucial development on October 9, this strategic move aims to enable wholesalers to fulfil their legal obligation to supply these essential medicines to patients across the UK. The updated list of drugs incorporated "all" available strengths and pharmaceutical formulations, ensuring comprehensive coverage for patients' medical needs.

The Department of Health and Social Care (DHSC) on Thursday (30th November) announced the launch of a new suicide surveillance system, bolstering its efforts to tackle emerging methods of suicide and clamp down on those seeking to sell dangerous products to vulnerable people. For now, the DHSC will work with the National Police Chiefs' Council to gather near to real-time data from across the country on deaths by suspected suicide by gender, age group and method. The data will be obtained from individual police forces in England and the government will get it within three months of a suspected suicide, the DHSC said in its release. Previously, the only suicide data available at a national level was provided by the Office for National Statistics (ONS), but it could take up to 2 years for the official ONS data to come through.

A new bill was introduced to Parliament on Wednesday (20 March) to prohibit the sale of tobacco to children under the age of 15, delivering on the Prime Minister's commitment to create a smokefree generation. The Tobacco and Vapes Bill aims to protect future generations from the harmful impacts of smoking, thereby saving thousands of lives and billions of pounds for the NHS. The bill will also introduce new powers to restrict vape flavours and packaging deliberately targeted towards children, as well as allow the government to change how they are displayed in shops, moving them out of sight of children and away from products that appeal to them, like sweets. Additionally, enforcement officers' powers will be strengthened with 'on the spot fines' of £100 to ensure compliance with the new laws. This complements the existing maximum fine of £2,500 that local authorities can already impose. It will also become illegal to provide free samples of vapes to children under the age of 18.